systemic immunosuppressive therapy with azathioprine or cyclosporin is limited by their adverse effects, or when the lesions are not controlled by systemic drugs alone.
References1 Moschella SL. Neutrophilic dermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. Mosby, London, 2003: 415 -418. 2 Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283. 3 Mrowietz U. Ascomycin macrolactams. J Cutan Med Surg 2001; 5: 22-25. 4 Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-280. 5 Lazarus GS, Rocklin RE, David JR. Pyoderma gangrenosum, altered delayed hypersensitivity, and polyarthritis. Arch Dermatol 1972; 105: 46-51. 6 Norris DA, Weston WI, Thorne G, Humbert JR. Pyoderma gangrenosum: abnormal monocyte function corrected in vitro with hydrocortisone. Arch Dermatol 1978; 114: 906 -911. 7 Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199 -203. 8 Groves RW, Allen MH, Ross EL, Barker JNWN, MacDonald DM. Tumour-necrosis factor alpha is proinflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995; 132: 345-352. 9 Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684. 10 Billich A, Aschauer H, Aszòdi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35.